GGrantIndex
← Search

Administrative Supplement: Early Career Cancer Clinical Investigator Award (ECIA)

$59,999P30FY2024CANIH

Emory University, Atlanta GA

Investigators

Linked publications, trials & patents

Trial NCT07405476Trial NCT07213154Trial NCT07174570Trial NCT07155317Trial NCT07150546Trial NCT07140679Trial NCT07112690Trial NCT07104240Trial NCT07101445Trial NCT06914999Trial NCT06868433Trial NCT06865768Trial NCT06799481Trial NCT06760507Trial NCT06731270Trial NCT06709534Trial NCT06708351Trial NCT06674863Trial NCT06662058Trial NCT06650579Trial NCT06636734Trial NCT06595160Trial NCT06583148Trial NCT06541158Trial NCT06534125Trial NCT06495125Trial NCT06492759Trial NCT06492070Trial NCT06423326Trial NCT06328699Trial NCT06328686Trial NCT06324240Trial NCT06254911Trial NCT06132685Trial NCT06105918Trial NCT06008730Trial NCT06006013Trial NCT05998135Trial NCT05877859Trial NCT05873608Trial NCT05798507Trial NCT05779943Trial NCT05756569Trial NCT05733351Trial NCT05526872Trial NCT05514912Trial NCT05513859Trial NCT05506982Trial NCT05493566Trial NCT05488145Trial NCT05464810Trial NCT05391750Trial NCT05387915Trial NCT05368428Trial NCT05346692Trial NCT05341349Trial NCT05320406Trial NCT05315687Trial NCT05310448Trial NCT05274763Trial NCT05250895Trial NCT05245682Trial NCT05244239Trial NCT05208307Trial NCT05204160Trial NCT05103904Trial NCT05091866Trial NCT05086731Trial NCT05039073Trial NCT05017610Trial NCT04908709Trial NCT04895592Trial NCT04890236Trial NCT04883437Trial NCT04878029Trial NCT04848519Trial NCT04776395Trial NCT04762199Trial NCT04754945Trial NCT04750473Trial NCT04731376Trial NCT04725903Trial NCT04676087Trial NCT04590664Trial NCT04585724Trial NCT04524702Trial NCT04483206Trial NCT04433949Trial NCT04428671Trial NCT04393350Trial NCT04366791Trial NCT04361552Trial NCT04352205Trial NCT04348292Trial NCT04340882Trial NCT04278118Trial NCT04276194Trial NCT04262869Trial NCT04191421Trial NCT04144127

Abstract

PROJECT SUMMARY/ABSTRACT Dr. Manali Bhave is an academic medical oncologist with a research focus on early phase therapeutic clinical trial development involving novel targeted therapies and immunomodulatory strategies for the treatment of breast cancer. Her goal is to lead institutional investigator-initiated and NCI-sponsored cooperative group clinical trials that will further advance the fight against cancer. Dr. Bhave plays a critical role in Winship’s clinical trial program and is extensively involved in NCI-sponsored clinical trials. She is an active member on multiple national committees including the Breast Cancer Working Groups for SWOG and ETCTN, and plans to expand her involvement with ECOG-ACRIN and her role within ETCTN as Emory’s Breast lead. She is the institutional principal investigator of two NCI- sponsored clinical trials, three investigator-initiated clinical trials at Winship and one investigator- initiated clinical trial currently under development through SWOG. She also contributes as an active co-investigator on numerous others. As a phase I and breast oncology leader at Winship, Dr. Bhave is an important contributor to patient enrollment to NCTN and ETCTN trials. She is Vice Chair of Winship’s Data & Safety Monitoring Committee, Medical Director of the Phase I Clinical Trials Unit and Phase I Working Group Lead. In these roles, she has shown tremendous growth as a leader to broaden the clinical trial portfolio, improve access to phase I clinical trials, and increase faculty engagement in the Phase I program. Winship Cancer Institute of Emory University fully supports Dr. Bhave in her career goals to advance as a national leader in clinical trials for breast cancer and early phase therapeutics, and in her ongoing efforts to enhance the clinical trial program at Winship. The ECIA award will support protected time for Dr. Bhave to focus on key initiatives to increase trial accrual at Winship through building a stronger phase I clinical trials infrastructure, and further develop her own promising protocol concepts at the national level. The ECIA funding mechanism will undoubtedly help foster academic growth and lead to further leadership roles within Winship and the NCI Trial Networks.

View original record on NIH RePORTER →